» Articles » PMID: 35486354

Cryptococcus Spp. and Cryptococcosis: Focusing on the Infection in Brazil

Overview
Specialty Microbiology
Date 2022 Apr 29
PMID 35486354
Authors
Affiliations
Soon will be listed here.
Abstract

Cryptococcosis is a global fungal infection caused by the Cryptococcus neoformans/Cryptococcus gattii yeast complex. This infection is acquired by inhalation of propagules such as basidiospores or dry yeast, initially causing lung infections with the possibility of progressing to the meninges. This infection mainly affects immunocompromised HIV and transplant patients; however, immunocompetent patients can also be affected. This review proposes to evaluate cryptococcosis focusing on studies of this mycosis in Brazilian territory; moreover, recent advances in the understanding of its virulence mechanism, animal models in research are also assessed. For this, literature review as realized in PubMed, Scielo, and Brazilian legislation. In Brazil, cryptococcosis has been identified as one of the most lethal fungal infections among HIV patients and C. neoformans VNI and C. gattii VGII are the most prevalent genotypes. Moreover, different clinical settings published in Brazil were described. As in other countries, cryptococcosis is difficult to treat due to a limited therapeutic arsenal, which is highly toxic and costly. The presence of a polysaccharide capsule, thermo-tolerance, production of melanin, biofilm formation, mechanisms for iron use, and morphological alterations is an important virulence mechanism of these yeasts. The introduction of cryptococcosis as a compulsory notification disease could improve data regarding incidence and help in the management of these infections.

Citing Articles

Novel mitochondrial-targeted alkyl chains act as fungal specific inhibitors of .

Edrich E, Young L, Spencer J, McGown A, Moore A, Gourlay C Front Microbiol. 2025; 15:1505308.

PMID: 39968045 PMC: 11832467. DOI: 10.3389/fmicb.2024.1505308.


Paving the way for affordable and equitable liposomal amphotericin B access worldwide.

Lee J, Cohen R, Khan R, Burry J, Casas E, Chung H Lancet Glob Health. 2024; 12(9):e1552-e1559.

PMID: 39151989 PMC: 11345448. DOI: 10.1016/S2214-109X(24)00225-0.


Novel combinatorial approach: Harnessing HIV protease inhibitors to enhance amphotericin B's antifungal efficacy in cryptococcosis.

Alkashef N, Seleem M PLoS One. 2024; 19(8):e0308216.

PMID: 39088434 PMC: 11293717. DOI: 10.1371/journal.pone.0308216.


Global trends in and its interactions with the host immune system: a bibliometric analysis.

Tang S, Hao R, Liu X, He H, Tian Y, Jing T Front Immunol. 2024; 15:1397338.

PMID: 38774865 PMC: 11106374. DOI: 10.3389/fimmu.2024.1397338.


Molecular characterization of clinical and environmental isolates from the Cryptococcus neoformans/C. Gattii species complexes of Maceió, Alagoas, Brazil.

de Holanda Fonseca D, Silva D, de Albuquerque Maranhao F Braz J Microbiol. 2024; 55(2):1369-1380.

PMID: 38619732 PMC: 11153433. DOI: 10.1007/s42770-024-01313-1.


References
1.
Faggi E, Pini G, Campisi E . Use of magnetic beads to extract fungal DNA. Mycoses. 2005; 48(1):3-7. DOI: 10.1111/j.1439-0507.2004.01030.x. View

2.
Wirth F, Azevedo M, Goldani L . Molecular types of Cryptococcus species isolated from patients with cryptococcal meningitis in a Brazilian tertiary care hospital. Braz J Infect Dis. 2018; 22(6):495-498. PMC: 9425640. DOI: 10.1016/j.bjid.2018.11.002. View

3.
Baker L, Specht C, Donlin M, Lodge J . Chitosan, the deacetylated form of chitin, is necessary for cell wall integrity in Cryptococcus neoformans. Eukaryot Cell. 2007; 6(5):855-67. PMC: 1899242. DOI: 10.1128/EC.00399-06. View

4.
Zaragoza O, Garcia-Rodas R, Nosanchuk J, Cuenca-Estrella M, Rodriguez-Tudela J, Casadevall A . Fungal cell gigantism during mammalian infection. PLoS Pathog. 2010; 6(6):e1000945. PMC: 2887474. DOI: 10.1371/journal.ppat.1000945. View

5.
Sangalli-Leite F, Scorzoni L, de Paula E Silva A, da Silva J, de Oliveira H, Singulani J . Synergistic effect of pedalitin and amphotericin B against Cryptococcus neoformans by in vitro and in vivo evaluation. Int J Antimicrob Agents. 2016; 48(5):504-511. DOI: 10.1016/j.ijantimicag.2016.07.025. View